Pradaxa

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Patients requiring idarucizumab will likely be critically ill adults with comorbid conditions and have a high risk of mortality… (More)
Is this relevant?
2016
2016
Dabigatran etexilate or pradaxa, a novel oral anticoagulant, is a reversible, competitive, direct thrombin inhibitor. It is used… (More)
Is this relevant?
2015
2015
Pradaxa (dabigatran) is a direct thrombin inhibitor approved for prevention of stroke and systemic embolism in patients with non… (More)
Is this relevant?
2015
2015
For decades, the basis for anticoagulation therapy has been the inhibition of enzymes at various levels of the coagulation… (More)
Is this relevant?
2015
2015
Novel oral anticoagulants are effective and safe alternatives to vitamin-K antagonists for anticoagulation therapy. However… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
An analysis of complex examination of 110 patients with venous thromboembolism was made. The patients were separated into 2… (More)
Is this relevant?
2014
2014
Pharmaceutical companies don't have a particularly good reputation, for some very good reasons. But we can't let suspicions about… (More)
Is this relevant?
2012
2012
Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs… (More)
  • figure 2
  • figure 1
Is this relevant?
Review
2012
Review
2012
STUDY DESIGN The authors present a case report of a 72-year-old man who presented with back pain and lower extremity weakness… (More)
Is this relevant?
2010
2010
Dabigatran (Pradaxa) is a new oral, direct, selective and reversible thrombin inhibitor (factor IIa) acting as anticoagulant… (More)
Is this relevant?